Oscar Health: Scale Is Finally Showing Up On The Bottom-Line

Impact · against what's priced in

Oscar Health appears fundamentally undervalued despite recent momentum, with the market potentially lagging behind its bottom-line acceleration. The combination of margin expansion and a low P/S relative to peers suggests further upside potential.

OSCR+0.60

No priced-in read yet

In context

The company is demonstrating accelerating bottom-line performance and margin expansion while trading at a forward P/S of 0.50, which is 80% below the sector median.

Read from the article alone

• OSCRNew
• margin expansion▲233%
• revenue growth
• valuation
• health insurance
• undervalued

Top 2 movers · tap to explore